To provide an overview of the efficacy and safety of lemborexant in the treatment of insomnia disorder by assessing the currently available literature.
Data Sources
A literature search of PubMed was performed (2010 to March 2021) using the following search terms: lemborexant, sleep, orexin
Study Selection and Data Extraction
All relevant English-language studies were reviewed and considered, with a focus on phase 3 trials.
Data Synthesis
The efficacy and safety of lemborexant in the treatment of insomnia disorder in adults was demonstrated in 2 phase 3 trials. Lemborexant significantly reduced latency to persistent sleep compared with placebo. The first study also demonstrated a significant reduction compared with the active control zolpidem ER. Somnolence and headache were relatively common, but the marked adverse effects associated with other medications commonly used to treat insomnia, such as cognitive and psychomotor impairment and complex sleep-related behaviors, were not observed.
Relevance to Patient Care and Clinical Practice
Although nonpharmacological therapy is considered first-line treatment for insomnia disorder, pharmacological treatment is most commonly utilized. Lemborexant is a viable pharmacological treatment option for patients who are unable to tolerate the adverse effects associated with the most commonly prescribed medications for insomnia, such as benzodiazepines and sedative-hypnotics (Z drugs). This is especially true for geriatric patients, who may be more sensitive to these adverse effects.
Conclusion
Lemborexant can be recommended to treat insomnia disorder when pharmacological treatment is warranted. It has demonstrated efficacy in clinical trials and is likely better tolerated than most currently available treatment options.
Institute of Medicine, Committee on Sleep Medicine and Research; ColtenHRAltevogtBM. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. National Academies Press; 2006. doi:10.17226/11617
2.
Centers for Disease Control and Prevention. Sleep and sleep disorders. Accessed March 17, 2021. https://cdc.gov/sleep/index.html
3.
WatsonNFBadrMSBelenkyG, et al. Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38:843-844. doi:10.5664/jcsm.4950
4.
BixlerE.Sleep and society: an epidemiological perspective. Sleep Med. 2009;10(suppl 1):S3-S6. doi:10.1016/j.sleep.2009.07.005
GrandnerMAChakravortySPerlisMLOliverLGurubhagavatulaI.Habitual sleep deprivation associated with self-reported and objectively determined cardiometabolic risk factors. Sleep Med. 2014;15:42-50. doi:10.1016/j.sleep.2013.09.012
7.
LiuYWheatonAGChapmanDPCrotJB.Sleep duration and chronic diseases among US adults age 45 years and older: evidence from the 2010 Behavioral Risk Factor Surveillance System. Sleep. 2013;36:1421-1427. doi:10.5665/sleep.3028
8.
GallicchioLKalesanB.Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res. 2009;18:148-158. doi:10.1111/j.1365-2869.2008.00732.x
9.
KesslerRCBerglundPACoulouvratC, et al. Insomnia and the performance of US workers: results from the America Insomnia Survey. Sleep. 2011;34:1161-1171. doi:10.5665/SLEEP.1230
10.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.American Psychiatric Association; 2013.
11.
SateiaMJ.International classification of sleep disorders-third edition: highlights and modification. Chest. 2014;146:1387-1394. doi:10.1378/chest.14-0970
12.
SateiaMJBuysseDJKrystalADNeubauerDNHealdJL.Clinical practice guideline for pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307-349. doi:10.5664/jcsm.6470
13.
QaseemAKansagaraDForcieaMACookeMDenbergTD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165:125-133. doi:10.7326/M15-2175
14.
GlassJLanctôtKLHerrmannNSprouleBABustoUE.Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169. doi:10.1136/bmj.38623.768588.47
15.
SchroeckJLFordJConwayEL, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38:2340-2372. doi:10.1016/j.clinthera.2016.09.010
16.
JordanASO’DonoghueFLCoriJMTrinderJ.Physiology of arousal in obstructive sleep apnea and potential impacts for sedative treatment. Am J Respir Crit Care Med. 2017;196:814-821. doi:10.1164/rccm.201612-2511PP
17.
MasonMCatesCJSmithI.Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnea. Cochrane Database Syst Rev. 2015;(7):CD011090. doi:10.1002/14651858.CD011090.pub2
18.
LyphoutCYatesCMargolinZR, et al. Presentations to the emergency department with non-medical use of benzodiazepines and Z-drugs: profiling and relation to sales data. Eur J Clin Pharmacol. 2019;75:77-85. doi:10.1007/s00228-018-2550-1
19.
TangSHuangWLuS, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017Feb;88:55-61. doi:10.1016/j.peptides.2016.12.008
20.
MichelsonDSnyderEParadisE, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461-471. doi:10.1016/S1474-4422(14)70053-5
21.
WangCWangQJiB, et al. The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci. 2018;11:220. doi:10.3389/fnmol.2018.00220
22.
MuehlanCVaillantCZenklusenIKraehenbuehlSDingemanseJ.Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16:1063-1078. doi:10.1080/17425255.2020.1817380
23.
BeuckmannCTSuzukiMUenoTNagaokaKAraiTHigashiyamaH.In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017;362:287-295. doi:10.1124/jpet.117.241422.
24.
MiedaMSakuraiT.Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs. 2013;27:83-90. doi:10.1007/s40263-012-0036-8
25.
MurphyPMolineMMaylebenD, et al. Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med. 2017;13:1289-1299. doi:10.5664/jcsm.6800
26.
EquihuaACDe La Herrán-AritaAKDrucker-ColinR.Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol. 2013;4:163. doi:10.3389/fphar.2013.00163
27.
KumarAChananaPChoudharyS.Emerging role of orexin antagonists in insomnia therapeutics: an update on SORAs and DORAs. Pharmacol Rep. 2016;68:231-242. doi:10.1016/j.pharep.2015.09.002
28.
VermeerenAJongenSMurphyP, et al. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42:zsy260. doi:10.1093/sleep/zsy260
29.
de LeceaLRamónH. Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;5:16. doi:10.3389/fphar.2014.00016
30.
FulcherBDPhillipsAJKPostnovaSRobinsonPA.A physiologically based model of orexinergic stabilization of sleep and wake. PLoS One. 2014;9:e91982. doi:10.1371/journal.pone.0091982
31.
WillieJTChemelliRMSintonCM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron. 2003;38:715-730. doi:10.1016/s0896-6273(03)00330-1
32.
DugovicCSheltonJEAluisioLE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009;330:142-151. doi:10.1124/jpet.109.152009
33.
LandryIAluriJHallN, et al. Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant. Pharmacol Res Perspect. 2020;8:e00678. doi:10.1002/prp2.678
34.
LandryINakaiKFerryJ, et al. Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults. Clin Pharmacol Drug Dev. 2021;10:153-165. doi:10.1002/cpdd.817
35.
KärppäMYardleyJPinnerK, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE2. Sleep. 2020;43:zsaa123. doi:10.1093/sleep/zsaa123
36.
Lemborexant. Package insert. Eisai Inc; 2019.
37.
RosenbergRMurphyPZammitG, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2:e1918254. doi:10.1001/jamanetworkopen.2019.18254
38.
YardleyJKärppäMInoueY, et al. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med. 2021;80:333-342. doi:10.1016/j.sleep.2021.01.048
39.
ChengJYFilippovGMolineMZammitGKBsharatMHallN.Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double-blind, placebo-controlled, crossover study. J Sleep Res. 2020;29:e13021. doi:10.1111/jsr.13021
40.
ChengJYMolineMZammitGKFilippovGBsharatMHallN.Respiratory safety of lemborexant in healthy subjects: a single-dose, randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. Published online March 16, 2021. doi:10.1007/s40261-021-01018-5
41.
MatzeuAMartin-FardonR.Blockade of orexin receptors in the posterior paraventricular nucleus of the thalamus prevents stress-induced reinstatement of reward-seeking behavior in rats with a history of ethanol dependence. Front Integr Neurosci. 2020;14:599710. doi:10.3389/fnint.2020.599710
42.
Esmaili-Shahzade-Ali-AkbariPHosseinzadehHMehriS.Effect of suvorexant on morphine tolerance and dependence in mice: role of NMDA, AMPA, ERK and CRED proteins. Neurotoxicology. 2021;84:64-72. doi:10.1016/j.neuro.2021.02.005
43.
MorinCMBellevilleGBélangerLIversH.The Insomnia Severity Index: psychometric indicators to detect cases and evaluate treatment response. Sleep. 2011;34:601-608. doi:10.1093/sleep/34.5.601
